CNS Pharmaceuticals Inc. (NASDAQ: CNSP) stock gains by 8.46% in the current market trading session. CNS Pharmaceuticals is a clinical-stage pharmaceutical business researching anti-cancer medication candidates for the cure of brain and central nervous system tumors, both primary and metastatic.
What is happening?
The US Food and Drug Administration (FDA) has given Berubicin, which is CNS Pharmaceuticals’ main experimental drug, Fast Track Designation for the cure of patients with persistent glioblastoma multiforme (GBM). The FDA has also granted Berubicin Orphan Drug Designation for the treatment of individuals with recurrent GBM, as reported earlier.
Berubicin is an anthracycline, a kind of anticancer medication that is one of the most potent and efficient against more cancer types than any other.
Fast Track Designation allows for more regular interactions with the FDA in order to speed up the development and evaluation process for medicines that are intended to treat serious or life-threatening diseases and have the potential to meet an unmet medical need. The commencement of patient enrolment in CNS’s potentially important trial of Berubicin for the prevention of chronic glioblastoma multiforme was recently announced.
John Climaco, CEO of CNS Pharmaceuticals stated,
Receiving Fast Track Designation from the US Food and Drug Administration is a significant step forward in the development of Berubicin for the treatment of glioblastoma, the most aggressive, fatal, and treatment-resistant kind of brain cancer. GBM is one of those diseases when the unmet clinical need requires action. Patients have few alternatives, and thousands of people die each year as a result of this dreadful illness. CNSP now has faster road to approval for Berubicin, and a clear chance to provide this potentially life-changing experimental treatment to people fighting this difficult disease more quickly.